FDA staff stated the compound lacks sufficient information to know whether the drug would cause harm when administered to humans. The committees public docket drew approximately 1,860 comments before the July 23-24 hearing, reflecting broad interest from patients, clinicians, and compounding pharmacists
Until that time, the majority of evidence seems to point to a potential benefit of antioxidants in the management of male infertility
Impairments, disabilities and handicap pattern in konzoa non-progressive spastic para/tetraparesis of acute onset
You have a ligand, you have a receptor, and the experiments follow: binding assays, competition curves, functional readouts through a known G protein, receptor-expressing cell lines, selective antagonist controls
Rodriguez-Barraquer, I
Both trials compared CYMBALTA 60 mg once daily or 60 mg twice daily with placebo